Publications

Atreya CE, Yaeger R, Chu E. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2017. PMID: 28561718

Parikh A, Atreya C, Korn WM, Venook AP. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2017. PMID: 28040715

GBD 2015 Eastern Mediterranean Region Diarrhea Collaborators. Burden of diarrhea in the Eastern Mediterranean Region, 1990-2015: Findings from the Global Burden of Disease study Int J Public Health. 2017. PMID:

Venook AP. Right-sided vs left-sided colorectal cancer. Clinical advances in hematology & oncology : H&O. 2017. PMID: 28212365

Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer. Clinical breast cancer. 2016. PMID: 28110902

Oh DY, Cham J, Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. Cancer research. 2016. PMID: 28031229

Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer discovery. 2016. PMID: 28031159

Adler E, Dhruva A, Moran PJ, Daubenmier J, Acree M, Epel ES, Bacchetti P, Prather AA, Mason A, Hecht FM. Impact of a Mindfulness-Based Weight-Loss Intervention on Sleep Quality Among Adults with Obesity: Data from the SHINE Randomized Controlled Trial. Journal of alternative and complementary medicine (New York, N.Y.). 2016. PMID: 28029852

Cheung EO, Cohn MA, Dunn LB, Melisko ME, Morgan S, Penedo FJ, Salsman JM, Shumay DM, Moskowitz JT. A randomized pilot trial of a positive affect skill intervention (lessons in linking affect and coping) for women with metastatic breast cancer. Psycho-oncology. 2016. PMID: 27862646

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. Journal for immunotherapy of cancer. 2016. PMID: 28018601

Thiagarajan PS, Wu X, Zhang W, Shi I, Bagai R, Leahy P, Feng Y, Veigl M, Lindner D, Danielpour D, Yin L, Rosell R, Bivona TG, Zhang Z, Ma PC. Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming. Oncotarget. 2016. PMID: 27852038

Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, Badham N, Rafiq R, Brough R, Gulati A, Ryan CJ, Francis J, Vermulen PB, Reynolds AR, Reaper PM, Pollard JR, Ashworth A, Lord CJ. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nature communications. 2016. PMID: 27958275

Urisman A, Levin RS, Gordan JD, Webber JT, Hernandez H, Ishihama Y, Shokat KM, Burlingame AL. An Optimized Chromatographic Strategy for Multiplexing In Parallel Reaction Monitoring Mass Spectrometry: Insights from Quantitation of Activated Kinases. Molecular & cellular proteomics : MCP. 2016. PMID: 27940637

van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S. Assessing Researcher Needs for a Virtual Biobank. Biopreservation and biobanking. 2016. PMID: 27929677

Algazi AP, Grandis JR. Head and neck cancer in 2016: A watershed year for improvements in treatment? Nature reviews. Clinical oncology. 2016. PMID: 27922045

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast (Edinburgh, Scotland). 2016. PMID: 27927580

Courtney D DiNardo, Joseph Rosenthal, Michael Andreeff, Oleg Zernovak, Prasanna Kumar, Roohi Gajee, Shuquan Chen, Michael Rosen, Saeheum Song, Jarema Kochan, Tharin Limsakun, Rebecca Olin. Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results. Blood. 2016. PMID:

Huimin Geng, Huaxin Gao, Cigall Kadoch, Ming Lu, Lingjing Chen, Rana Anjum, Lisa Drew, Sebastien Degorce, Keith Dillman, Michele Mayo, Shawn Anderson, Colin Collins, Clifford A. Lowell, James L. Rubenstein. Targeting NF-KB Activation in Novel Intracranial Models of CNS Lymphoma. Blood. 2016. PMID:

Atreya CE, Venook AP. Role of Biologics in Colon Cancer: Still Not Clear. Journal of oncology practice. 2016. PMID: 27943687

Majure M, Logan AC. What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer. Annals of translational medicine. 2016. PMID: 28149904